Nanoparticle-Wrapped Milk Peptide Fights Mastitis Bacteria Without Antibiotics | Research

The takeaway

Bovine lactoferricin wrapped in chitosan nanoparticles showed enhanced antibacterial activity against mastitis-causing bacteria and reduced infection in mice without toxicity.

72% encapsulation
Chitosan nanoparticles encapsulated 72% of the lactoferricin payload, significantly enhancing its antibacterial activity over the free peptide

What the researchers found

Encapsulating bovine lactoferricin (BLfcin) — an antimicrobial peptide from milk — in chitosan nanoparticles significantly enhanced its antibacterial activity against S. aureus and E. coli compared to the free peptide. The nanoparticles were 101–136 nm in size with 72% encapsulation efficiency.

In a mouse model of mastitis (breast infection), the BLfcin nanoparticles reduced bacterial load, decreased mammary inflammation, and boosted antioxidant enzyme levels without causing toxicity. Transcriptomic analysis revealed that the nanoparticle formulation suppressed bacterial genes related to ribosomes, ABC transporters, and two-component signaling systems — explaining the enhanced killing.

Why it matters

Mastitis is the most costly disease in dairy farming, and antibiotic overuse for treatment drives antimicrobial resistance. Lactoferricin is a natural antimicrobial peptide found in milk itself, making it an appealing antibiotic alternative. But like many peptides, free BLfcin is unstable and breaks down quickly. Wrapping it in chitosan nanoparticles solves this problem — improving stability, activity, and efficacy in living animals. This represents a practical, antibiotic-free approach to one of agriculture's biggest infection problems.

The numbers in context

NPs 101.2–135.9 nm · zeta potential +19.83 to +21.37 mV · 72.18% encapsulation efficiency · improved activity vs S. aureus + E. coli · reduced bacterial burden in mouse mastitis · no toxicity observed

How the study worked

BLfcin was loaded into chitosan nanoparticles and characterized for size, charge, and encapsulation efficiency. Antibacterial activity was tested in vitro against S. aureus and E. coli. Transcriptomic analysis identified bacterial gene expression changes caused by BLfcin NPs. Efficacy was validated in a murine mastitis model, measuring bacterial burden, inflammatory markers, antioxidant enzyme levels, and tissue toxicity.

Who was studied

In vitro bacterial cultures (S. aureus, E. coli) and murine mastitis model

What this study cannot tell us

Mouse mastitis models don't perfectly replicate bovine udder physiology. The study does not test the nanoparticles in actual dairy cattle. Long-term stability of the nanoparticle formulation during storage is not addressed. The transcriptomic analysis was performed in vitro and may not capture all in vivo bacterial responses. Cost-effectiveness compared to conventional antibiotics is not evaluated.

How to read the evidence

This is a preclinical study combining in vitro antibacterial testing with transcriptomics and a mouse mastitis model. The 'Moderate' grade reflects the thorough multi-approach methodology, though translation to dairy cattle is still needed.

When this study was published

Published in 2026, this is a very recent study representing the cutting edge of antimicrobial peptide nanoparticle delivery for veterinary applications.

The bigger picture

The fight against antibiotic resistance in agriculture is driving innovation in antimicrobial peptide delivery. Lactoferricin is particularly elegant because it comes from the very milk being produced — a natural defense molecule repurposed as a therapeutic. Chitosan nanoparticle delivery solves the stability problem that has limited free peptide use in veterinary medicine. If this approach scales to dairy cattle, it could significantly reduce antibiotic use in one of the largest agricultural sectors.

Questions still open

How does the cost of BLfcin nanoparticle treatment compare to conventional antibiotic mastitis therapy?
Would this approach work directly in dairy cows with naturally occurring mastitis?
Could lactoferricin nanoparticles be administered through intramammary infusion for localized treatment?

Common questions

What is lactoferricin and where does it come from?

Lactoferricin (BLfcin) is a naturally occurring antimicrobial peptide released when the protein lactoferrin in cow's milk is digested by stomach enzymes. It kills bacteria by disrupting their cell membranes. Using a peptide that naturally occurs in milk to fight mastitis — an infection of the milk-producing gland — is an elegant biological approach to a major agricultural problem.

Why wrap the peptide in nanoparticles instead of using it directly?

Free lactoferricin breaks down quickly in biological environments, limiting its effectiveness. Chitosan nanoparticles protect the peptide from degradation, release it in a controlled manner, and because chitosan itself has mild antibacterial properties, the combination works better than either component alone. The positive charge of the nanoparticles also helps them stick to negatively charged bacterial surfaces.

Read the original research

Chitosan Nanoparticle Delivery Enhances the Antibacterial Performance and Bioactivity of Bovine Lactoferricin against Staphylococcus aureus-Associated Mastitis.

Journal of agricultural and food chemistry, 74(1), 1422-1436

View on PubMed ↗Publisher’s paper ↗

Citation

Wang, Kaiming; Gao, Yumeng; Jiang, Zhenlin; Tong, Jinjin; Zhang, Hua. (2026). Chitosan Nanoparticle Delivery Enhances the Antibacterial Performance and Bioactivity of Bovine Lactoferricin against Staphylococcus aureus-Associated Mastitis.. Journal of agricultural and food chemistry, 74(1), 1422-1436. https://doi.org/10.1021/acs.jafc.5c08818